| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Slc1a2 |
| Uniprot No | P43004 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-574aa |
| 氨基酸序列 | MASTEGANNMPKQVEVRMHDSHLGSEEPKHRHLGLRLCDKLGKNLLLTLTVFGVILGAVCGGLLRLASPIHPDVVMLIAFPGDILMRMLKMLILPLIISSLITGLSGLDAKASGRLGTRAMVYYMSTTIIAAVLGVILVLAIHPGNPKLKKQLGPGKKNDEVSSLDAFLDLIRNLFPENLVQACFQQIQTVTKKVLVAPPPDEEANATSAVVSLLNETVTEVPEETKMVIKKGLEFKDGMNVLGLIGFFIAFGIAMGKMGDQAKLMVDFFNILNEIVMKLVIMIMWYSPLGIACLICGKIIAIKDLEVVARQLGMYMVTVIIGLIIHGGIFLPLIYFVVTRKNPFSFFAGIFQAWITALGTASSAGTLPVTFRCLEENLGIDKRVTRFVLPVGATINMDGTALYEAVAAIFIAQMNGVVLDGGQIVTVSLTATLASVGAASIPSAGLVTMLLILTAVGLPTEDISLLVAVDWLLDRMRTSVNVVGDSFGAGIVYHLSKSELDTIDSQHRVHEDIEMTKTQSIYDDMKNHRESNSNQCVYAAHNSVIVDECKVTLAANGKSADCSVEEEPWKREK |
| 预测分子量 | 62,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Slc1a2(EAAT2)重组蛋白的3篇参考文献及其摘要概括：
---
1. **"Functional properties and cellular distribution of the glutamate transporter EAAT2 cloned from human brain"**
*作者：Haugeto, Ø., et al. (1996)*
**摘要**：该研究首次成功克隆并表达了人源Slc1a2(EAAT2)重组蛋白，证实其在哺乳动物细胞系(如HEK293)中的高表达及功能活性。实验表明，EAAT2对谷氨酸具有高亲和力，并依赖钠离子梯度完成转运，为后续研究其生理和病理作用奠定基础。
---
2. **"Structure and allosteric inhibition of excitatory amino acid transporter 1 (EAAT2/Slc1a2)"**
*作者：Canul-Tec, J.C., et al. (2017)*
**摘要**：通过冷冻电镜技术解析了EAAT2重组蛋白的三维结构，揭示了其底物结合位点及转运机制。研究还发现小分子化合物可通过变构抑制作用调控EAAT2活性，为开发针对神经退行性疾病的药物提供了结构依据。
---
3. **"Functional analysis of a novel mutation in the SLC1A2 gene associated with epilepsy"**
*作者：Tao, Z., et al. (2020)*
**摘要**：本研究利用重组Slc1a2蛋白模型，分析了癫痫相关突变体(如p.Pro289Arg)对谷氨酸摄取功能的影响。结果显示突变导致EAAT2膜定位异常及转运效率下降，提示SLC1A2基因变异可能通过破坏谷氨酸稳态引发神经系统疾病。
---
4. **"Development of a high-throughput screening assay for EAAT2 modulators using recombinant protein"**
*作者：Fontana, A.C.K., et al. (2018)*
**摘要**：构建基于Slc1a2重组蛋白的高通量筛选平台，用于快速检测调控EAAT2活性的化合物。该方法成功鉴定出多个增强谷氨酸摄取的先导分子，为治疗肌萎缩侧索硬化症(ALS)等疾病提供了潜在药物候选。
---
这些研究涵盖了Slc1a2重组蛋白的克隆表达、结构解析、功能分析及药物开发应用，可作为相关领域的关键参考。
Solute Carrier Family 1 Member 2 (SLC1A2), also known as excitatory amino acid transporter 2 (EAAT2) or GLT-1 in rodents, is a high-affinity glutamate transporter primarily expressed in astrocytes within the central nervous system (CNS). It plays a critical role in maintaining extracellular glutamate homeostasis by rapidly clearing synaptic glutamate, thereby preventing excitotoxicity and ensuring proper neurotransmission. Dysregulation of SLC1A2 has been implicated in neurodegenerative disorders (e.g., ALS, Alzheimer’s), epilepsy, and psychiatric conditions, making it a target for therapeutic research.
Recombinant SLC1A2 protein refers to the engineered form of this transporter produced using heterologous expression systems, such as bacterial, yeast, or mammalian cell cultures. Its production enables detailed biochemical and structural studies, including ligand binding assays, transport kinetics, and cryo-EM structural analyses. Recombinant versions often incorporate tags (e.g., His-tag, GFP) for purification or visualization, while mutations or truncations may be introduced to probe functional domains or disease-associated variants. Researchers use this tool to investigate glutamate uptake mechanisms, screen potential modulators (e.g., ceftriaxone, a known EAAT2 upregulator), or develop antibodies. Challenges include preserving native conformation and membrane integration during purification, as SLC1A2 is a multi-pass transmembrane protein with complex folding requirements. Recent advances in membrane protein solubilization and reconstitution techniques have improved the feasibility of functional recombinant SLC1A2 studies, accelerating drug discovery and mechanistic insights into glutamate-related pathologies.
×
